Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade A 180.52 2.22% 3.92
VRTX closed up 2.22 percent on Thursday, September 20, 2018, on 73 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical VRTX trend table...

Date Alert Name Type % Chg
Sep 20 Crossed Above 20 DMA Bullish 0.00%
Sep 20 Crossed Above 50 DMA Bullish 0.00%
Sep 20 Stochastic Buy Signal Bullish 0.00%
Sep 20 Multiple of Ten Bullish Other 0.00%
Sep 19 NR7 Range Contraction 2.22%
Sep 19 Inside Day Range Contraction 2.22%
Sep 19 Oversold Stochastic Weakness 2.22%
Sep 18 50 DMA Resistance Bearish 1.92%
Sep 18 Spinning Top Other 1.92%
Sep 18 Stochastic Reached Oversold Weakness 1.92%

Older signals for VRTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 186.44
52 Week Low 136.5
Average Volume 1,079,836
200-Day Moving Average 162.9982
50-Day Moving Average 177.9924
20-Day Moving Average 179.976
10-Day Moving Average 178.461
Average True Range 3.4448
ADX 14.46
+DI 21.1571
-DI 18.0357
Chandelier Exit (Long, 3 ATRs ) 176.1056
Chandelier Exit (Short, 3 ATRs ) 184.5644
Upper Bollinger Band 185.8392
Lower Bollinger Band 174.1128
Percent B (%b) 0.55
BandWidth 6.515535
MACD Line 0.3757
MACD Signal Line 0.9055
MACD Histogram -0.5298
Fundamentals Value
Market Cap 45.52 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 173.58
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 186.51
Resistance 3 (R3) 186.13 183.75 185.51
Resistance 2 (R2) 183.75 182.23 183.94 185.17
Resistance 1 (R1) 182.14 181.29 182.95 182.52 184.84
Pivot Point 179.76 179.76 180.17 179.95 179.76
Support 1 (S1) 178.15 178.24 178.96 178.53 176.20
Support 2 (S2) 175.77 177.30 175.96 175.87
Support 3 (S3) 174.16 175.77 175.53
Support 4 (S4) 174.54